Daiichi Sankyo
DSKYFDrugs in Pipeline
138
Phase 3 Programs
76
Upcoming Catalysts
14
Next Catalyst
This month
Market Overview
Stock performance and key metrics
14 upcoming, 2 past
How DSKYF's past catalysts played out
Metformin HCl tablets and Colesevelam tablets
Type 2 Diabetes Mellitus
DU-176b (edoxaban)
Venous Thromboembolism
losartan potassium
Essential Hypertension
Olmesartan medoxomil 40 mg - Amlodipine 10 mg
Essential Hypertension
VKA-Based Regimen
Atrial Fibrillation
Olmesartan medoxomil
Atherosclerosis
Olmesartan medoxomil tablets low dose
Metabolic Syndrome
T-DM1
HER2-Positive Primary Breast Cancer
15mg DU-176b
Venous Thromboembolism
Colesevelam
Type 2 Diabetes
edoxaban tosylate(DU-176b)
Venous Thromboembolism
Salvage Chemotherapy
AML
olmesartan medoxomil + amlodipine + hydroclororthiazide
Essential Hypertension
enoxaparin sodium
Venous Thromboembolism
CHS-0214
Rheumatoid Arthritis
Rivoglitazone
Type 2 Diabetes
DS-8201a
Neoplasm, Gastrointestinal
Tivantinib
Metastatic Colorectal Cancer
Denosumab
Osteoporosis
DU-176b 15mg
Venous Thromboembolism
ofloxacin otic solution 0.3%
Otitis Media
DS-1062a
Non-small Cell Lung Cancer
CPT-11 and TS-1
Colorectal Cancer
Trastuzumab Deruxtecan
Gastric Cancer
exatecan mesylate
Esophageal Cancer
Warfarin Potassium
CTEPH
Hydrochlorothiazide
Hypertension
prasugrel
Diabetes Mellitus
Pemetrexed
Metastatic Non Small Cell Lung Cancer
Pioglitazone
Type 2 Diabetes Mellitus
Colesevelam HCl
Type 2 Diabetes
DU-176b 30mg
Non-valvular Atrial Fibrillation
Etoposide
Non-small Cell Lung Cancer
Clopidogrel
Peripheral Arterial Disease
Pregabalin
Pain Associated With Fibromyalgia
Nab-paclitaxel
Breast Cancer
Dato-DXd
Urothelial Cancer
gemcitabine hydrochloride
Pancreatic Cancer
Datopotamab Deruxtecan
Metastatic Non Small Cell Lung Cancer
olmesartan medoxomil + hydrochlorothiazide, if necessary
Essential Hypertension
Ramucirumab
Non-Small Cell Lung Cancer
OM 40
Hypertension
olmesartan medoxomil + hydrochlorothiazide
Essential Hypertension
CS-3150
Essential Hypertension
Vitamin K antagonist
Atrial Fibrillation
warfarin tablets
Stroke
edoxaban
Prevention
DS-5565
Pain Associated With Fibromyalgia
Pexidartinib
Tenosynovial Giant Cell Tumor
Amrubicin
Small Cell Lung Cancer
Olmesartan medoxomil plus amlodipine
Hypertension
Patritumab Deruxtecan
Nonsquamous Non-small Cell Lung Cancer
cevimeline hydrochloride
Head and Neck Cancer
nitrendipine + hydrochlorothiazide, if necessary
Isolated Systolic Hypertension
ASA
SCAD
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
Eribulin mesylate
Breast Cancer
Standard of Care (SOC)
Cardiac Disease
R-DXd
Solid Cancer
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
Platinum Chemotherapy
Non-small Cell Lung Cancer
Ifinatamab deruxtecan
Esophageal Squamous Cell Carcinoma
Welchol
Type 2 Diabetes Mellitus
DU-176b
Venous Thromboembolism
CS-8958
Influenza, Human
Chemotherapy
Acute Myeloid Leukemia
Edoxaban-based Regimen
Atrial Fibrillation
Eplerenone
Essential Hypertension
Mirogabalin
Diabetic Peripheral Neuropathic Pain
T-DXd
Advanced Cancer
Transdermal Patch
Trauma
Quizartinib
Leukemia
Eribulin
Breast Cancer
Dalteparin
Venous Thromboembolism (VTE)
Standard of Care
Venous Thromboembolism (VTE)
Colesevelam hydrochloride
Type 2 Diabetes
piclozotan
Parkinson's Disease
Patritumab Deruxtecan (Fixed dose)
Non-Small Cell Lung Cancer Metastatic
Carperitide
Heart Failure, Congestive
DS-5670a
Covid19
DU-176b tablets
Atrial Fibrillation
soblidotin
Lung Cancer
DS-8500a 25 mg
Type 2 Diabetes Mellitus
VN-0200
Respiratory Syncytial Virus Infections
DS-3939a
Advanced Solid Tumor
Valemetostat Tosylate
Adult T-cell Leukemia/Lymphoma
Quizartinib High Dose
Acute Myeloid Leukemia
DS-1040b
Acute Ischemic Stroke
DS-1001b
WHO Grade II Glioma
AC220
Leukemia, Myeloid, Acute
Compound AC220
Acute Myeloid Leukemia
Ifinatamab deruxtecan (I-DXd)
Advanced Solid Tumor
CS-1008 (humanized anti-DR5 antibody)
Pancreatic Cancer
DJ-927
Colorectal Cancer
U3-1287
NSCLC (Advanced Non-small Cell Lung Cancer)
10mg DS-8500a tablet
Type 2 Diabetes Mellitus
PLX3397
Hodgkin Lymphoma
Rivoglitazone HCl
Type 2 Diabetes
Raludotatug deruxtecan
Advanced Solid Tumor
CS7017 tablets
Metastatic Non-small Cell Lung Cancer
DS-1211b
Pseudoxanthoma Elasticum
Pactimibe, CS-505
Coronary Heart Disease
CS7017
Colorectal Cancer
Warfarin potassium tablets
Atrial Fibrillation
edoxaban tosylate
Deep Vein Thrombosis
SUN13837 injection
Acute Spinal Cord Injury
Edoxaban (DU-176b)
Atrial Fibrillation
CS-1008
Non-small Cell Lung Cancer
HER3-DXd
Advanced Solid Tumor
DS-7011a
Systemic Lupus Erythematosus
CS-7017
Advanced Non-small Cell Lung Cancer (NSCLC)
5 mg ASB17061
Atopic Dermatitis
DS-8201a 5.4 mg/kg Q3W
Advanced Colorectal Cancer
CS-1008 2 mg/kg
Advanced Hepatocellular Carcinoma
SUN13834
Atopic Dermatitis
DS-5141b
Duchenne Muscular Dystrophy
CS-917
Diabetes Mellitus, Type 2
DS-5565 tablet
Diabetic Peripheral Neuropathy
DS3790a
Hematological Malignancies
SUN11031 20 ΞΌg/kg
Cachexia
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Thrombosis
Trastzumab Deruxtecan
Ovarian Cancer
U3-1402
Metastatic Breast Cancer
Pregabalin capsules
Pain
FOLFOX
Malignant Solid Tumour
Pharmacological intensification based on olmesartan
Ischemic Stroke
Enhertu
Prostate Cancer Metastatic
Valemetostat
Lymphoma
Sitagliptin 100 mg
Type 2 Diabetes Mellitus
Rescue Medications
Gastroesophageal Junction
89Zr-Patritumab deruxtecan
Non-Small Cell Lung Carcinoma
Abraxane alone
Breast Cancer
efatutazone
Anaplastic Thyroid Cancer
MK-1084
Lung Neoplasm Malignant
Gocatamig
Small Cell Lung Cancer Extensive Stage
Intrathecal (IT) triple chemotherapy prophylaxis
Acute Myeloid Leukemia
Dexrazoxane
Acute Myeloid Leukemia in Children
I-DXd
Oesophageal Squamous Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Metformin HCl tablets and Colesevelam tablets | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DU-176b (edoxaban) | Phase 3 | Venous Thromboembolism | - | - |
losartan potassium | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil 40 mg - Amlodipine 10 mg | Phase 3 | Essential Hypertension | - | - |
VKA-Based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Olmesartan medoxomil | Phase 3 | Atherosclerosis | - | - |
Olmesartan medoxomil tablets low dose | Phase 3 | Metabolic Syndrome | - | - |
T-DM1 | Phase 3 | HER2-Positive Primary Breast Cancer | - | - |
15mg DU-176b | Phase 3 | Venous Thromboembolism | - | - |
Colesevelam | Phase 3 | Type 2 Diabetes | - | - |
edoxaban tosylate(DU-176b) | Phase 3 | Venous Thromboembolism | - | - |
Salvage Chemotherapy | Phase 3 | AML | - | - |
olmesartan medoxomil + amlodipine + hydroclororthiazide | Phase 3 | Essential Hypertension | - | - |
enoxaparin sodium | Phase 3 | Venous Thromboembolism | - | - |
CHS-0214 | Phase 3 | Rheumatoid Arthritis | - | - |
Rivoglitazone | Phase 3 | Type 2 Diabetes | - | - |
DS-8201a | Phase 3 | Neoplasm, Gastrointestinal | - | - |
Tivantinib | Phase 3 | Metastatic Colorectal Cancer | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
DU-176b 15mg | Phase 3 | Venous Thromboembolism | - | - |
ofloxacin otic solution 0.3% | Phase 3 | Otitis Media | - | - |
DS-1062a | Phase 3 | Non-small Cell Lung Cancer | - | - |
CPT-11 and TS-1 | Phase 3 | Colorectal Cancer | - | - |
Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer | - | - |
exatecan mesylate | Phase 3 | Esophageal Cancer | - | - |
Warfarin Potassium | Phase 3 | CTEPH | - | - |
Hydrochlorothiazide | Phase 3 | Hypertension | - | - |
prasugrel | Phase 3 | Diabetes Mellitus | - | - |
Pemetrexed | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Colesevelam HCl | Phase 3 | Type 2 Diabetes | - | - |
DU-176b 30mg | Phase 3 | Non-valvular Atrial Fibrillation | - | - |
Etoposide | Phase 3 | Non-small Cell Lung Cancer | - | - |
Clopidogrel | Phase 3 | Peripheral Arterial Disease | - | - |
Pregabalin | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
Dato-DXd | Phase 3 | Urothelial Cancer | - | - |
gemcitabine hydrochloride | Phase 3 | Pancreatic Cancer | - | - |
Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
olmesartan medoxomil + hydrochlorothiazide, if necessary | Phase 3 | Essential Hypertension | - | - |
Ramucirumab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
OM 40 | Phase 3 | Hypertension | - | - |
olmesartan medoxomil + hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
CS-3150 | Phase 3 | Essential Hypertension | - | - |
Vitamin K antagonist | Phase 3 | Atrial Fibrillation | - | - |
warfarin tablets | Phase 3 | Stroke | - | - |
edoxaban | Phase 3 | Prevention | - | - |
DS-5565 | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Pexidartinib | Phase 3 | Tenosynovial Giant Cell Tumor | - | - |
Amrubicin | Phase 3 | Small Cell Lung Cancer | - | - |
Olmesartan medoxomil plus amlodipine | Phase 3 | Hypertension | - | - |
Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer | - | - |
cevimeline hydrochloride | Phase 3 | Head and Neck Cancer | - | - |
nitrendipine + hydrochlorothiazide, if necessary | Phase 3 | Isolated Systolic Hypertension | - | - |
ASA | Phase 3 | SCAD | - | - |
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
Eribulin mesylate | Phase 3 | Breast Cancer | - | - |
Standard of Care (SOC) | Phase 3 | Cardiac Disease | - | - |
R-DXd | Phase 3 | Solid Cancer | - | - |
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
Platinum Chemotherapy | Phase 3 | Non-small Cell Lung Cancer | - | - |
Ifinatamab deruxtecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
Welchol | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DU-176b | Phase 3 | Venous Thromboembolism | - | - |
CS-8958 | Phase 3 | Influenza, Human | - | - |
Chemotherapy | Phase 3 | Acute Myeloid Leukemia | - | - |
Edoxaban-based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Eplerenone | Phase 3 | Essential Hypertension | - | - |
Mirogabalin | Phase 3 | Diabetic Peripheral Neuropathic Pain | - | - |
T-DXd | Phase 3 | Advanced Cancer | - | - |
Transdermal Patch | Phase 3 | Trauma | - | - |
Quizartinib | Phase 3 | Leukemia | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
Dalteparin | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Standard of Care | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Colesevelam hydrochloride | Phase 3 | Type 2 Diabetes | - | - |
piclozotan | Phase 2 | Parkinson's Disease | - | - |
Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Carperitide | Phase 2 | Heart Failure, Congestive | - | - |
DS-5670a | Phase 2 | Covid19 | - | - |
DU-176b tablets | Phase 2 | Atrial Fibrillation | - | - |
soblidotin | Phase 2 | Lung Cancer | - | - |
DS-8500a 25 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
VN-0200 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
DS-3939a | Phase 2 | Advanced Solid Tumor | - | - |
Valemetostat Tosylate | Phase 2 | Adult T-cell Leukemia/Lymphoma | - | - |
Quizartinib High Dose | Phase 2 | Acute Myeloid Leukemia | - | - |
DS-1040b | Phase 2 | Acute Ischemic Stroke | - | - |
DS-1001b | Phase 2 | WHO Grade II Glioma | - | - |
AC220 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Compound AC220 | Phase 2 | Acute Myeloid Leukemia | - | - |
Ifinatamab deruxtecan (I-DXd) | Phase 2 | Advanced Solid Tumor | - | - |
CS-1008 (humanized anti-DR5 antibody) | Phase 2 | Pancreatic Cancer | - | - |
DJ-927 | Phase 2 | Colorectal Cancer | - | - |
U3-1287 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
10mg DS-8500a tablet | Phase 2 | Type 2 Diabetes Mellitus | - | - |
PLX3397 | Phase 2 | Hodgkin Lymphoma | - | - |
Rivoglitazone HCl | Phase 2 | Type 2 Diabetes | - | - |
Raludotatug deruxtecan | Phase 2 | Advanced Solid Tumor | - | - |
CS7017 tablets | Phase 2 | Metastatic Non-small Cell Lung Cancer | - | - |
DS-1211b | Phase 2 | Pseudoxanthoma Elasticum | - | - |
Pactimibe, CS-505 | Phase 2 | Coronary Heart Disease | - | - |
CS7017 | Phase 2 | Colorectal Cancer | - | - |
Warfarin potassium tablets | Phase 2 | Atrial Fibrillation | - | - |
edoxaban tosylate | Phase 2 | Deep Vein Thrombosis | - | - |
SUN13837 injection | Phase 2 | Acute Spinal Cord Injury | - | - |
Edoxaban (DU-176b) | Phase 2 | Atrial Fibrillation | - | - |
CS-1008 | Phase 2 | Non-small Cell Lung Cancer | - | - |
HER3-DXd | Phase 2 | Advanced Solid Tumor | - | - |
DS-7011a | Phase 2 | Systemic Lupus Erythematosus | - | - |
CS-7017 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | - | - |
5 mg ASB17061 | Phase 2 | Atopic Dermatitis | - | - |
DS-8201a 5.4 mg/kg Q3W | Phase 2 | Advanced Colorectal Cancer | - | - |
CS-1008 2 mg/kg | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
SUN13834 | Phase 2 | Atopic Dermatitis | - | - |
DS-5141b | Phase 2 | Duchenne Muscular Dystrophy | - | - |
CS-917 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
DS-5565 tablet | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
DS3790a | Phase 2 | Hematological Malignancies | - | - |
SUN11031 20 ΞΌg/kg | Phase 2 | Cachexia | - | - |
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor | Phase 2 | Thrombosis | - | - |
Trastzumab Deruxtecan | Phase 2 | Ovarian Cancer | - | - |
U3-1402 | Phase 2 | Metastatic Breast Cancer | - | - |
Pregabalin capsules | Phase 2 | Pain | - | - |
FOLFOX | Phase 2 | Malignant Solid Tumour | - | - |
Pharmacological intensification based on olmesartan | Phase 2 | Ischemic Stroke | - | - |
Enhertu | Phase 2 | Prostate Cancer Metastatic | - | - |
Valemetostat | Phase 2 | Lymphoma | - | - |
Sitagliptin 100 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Rescue Medications | Phase 2 | Gastroesophageal Junction | - | - |
89Zr-Patritumab deruxtecan | Phase 2 | Non-Small Cell Lung Carcinoma | - | - |
Abraxane alone | Phase 2 | Breast Cancer | - | - |
efatutazone | Phase 2 | Anaplastic Thyroid Cancer | - | - |
MK-1084 | Phase 2 | Lung Neoplasm Malignant | - | - |
Gocatamig | Phase 2 | Small Cell Lung Cancer Extensive Stage | - | - |
Intrathecal (IT) triple chemotherapy prophylaxis | Phase 2 | Acute Myeloid Leukemia | - | - |
Dexrazoxane | Phase 2 | Acute Myeloid Leukemia in Children | - | - |
I-DXd | Phase 2 | Oesophageal Squamous Cell Carcinoma | - | - |
Advanced solid tumors
1 drug in this indication
tenosynovial giant cell tumours
1 drug in this indication
First-line metastatic breast cancer
1 drug in this indication
HER2-low metastatic breast cancer
1 drug in this indication
Previously treated extensive-stage small cell lung cancer
1 drug in this indication
Advanced or metastatic solid tumours
1 drug in this indication
Dyslipidemia and cardiovascular risk
1 drug in this indication
Adjuvant treatment for HER2 positive early breast cancer with residual disease after neoadjuvant treatment
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown β the signals behind the verdict
Frequently asked questions
What is in Daiichi Sankyo's drug pipeline?β
CatalystAlert tracks 138 drug candidates in Daiichi Sankyo's (DSKYF) pipeline across Phase 3, Phase 2. Its lead program is Metformin HCl tablets and Colesevelam tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daiichi Sankyo's next FDA catalyst?β
Daiichi Sankyo's (DSKYF) next tracked catalyst is a Phase 3 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DSKYF biotech catalysts?β
Add DSKYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daiichi Sankyo's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.